N/A N=284 Bronchial Thermoplasty in Severe Persistent Asthma
Severe Asthma
Primary: Subjects Experiencing Severe Exacerbations (Rates) — 132; 118; 118; 106 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer
Lung Neoplasms
Primary: PD-L1 Prevalence IHC — 21; 14; 8; 27 Participants
N/A N=14 A Sleep Intervention in Type 1 Diabetes
Short Sleep Phenotype · Type1diabetes
Primary: Sleep Duration — 385; 388 minutes
N/A N=33 Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep
Non-visual Photoreception
Primary: Melatonin Suppression — 71.4; 70.1; 54.3; 32.5 Percentage suppression — p=0.73
Phase 1 N=72 A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
Myelodysplastic Syndrome · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Lead-in Cohort (LIC) — 12; 12; 8 Participants
N/A N=39 Optimizing Treatment Response in VA Specialized Intensive/Inpatient PTSD Programs
PTSD
Primary: Change in PTSD Symptoms — -23.86; -19.51 score on a scale
Phase 2 N=36 Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
Nephrotic Syndrome · Focal Segmental Glomerulosclerosis · Minimal Change Disease
Primary: Percentage of Participants in Renal Response at Day 113 — 0.0; 7.7; 12.5; 33.3 Percent of Participants
N/A N=15 Rezum FIM Optimization Study
Benign Prostatic Hyperplasia · Adenoma, Prostatic · Prostatic Adenoma
Primary: Change in International Prostate Symptom Score — -6.1; -12.9; -14.6; -14.8 score on a scale
Phase 2 N=15 PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Overall Response as Determined by iRECIST — 1; 1; 3; 9 Participants
Phase 2 N=100 Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
Liver Transplant · Liver Transplantation
Primary: The Percent of Participants Who Achieve Operational Tolerance 52 Weeks After Completion of Immunosuppression Withdrawal. — 16.4 Percent of Participants
N/A N=23 Clinical Evaluation of Laser Therapy Used as an Adjunct to Non-Surgical Treatment of Gum Disease
Periodontitis Chronic Generalized Moderate · Periodontitis Chronic Generalized Severe
Primary: Probing Pocket Depth — 4.167; 4.273 mm
Phase 2 N=72 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Phase 2 N=343 Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Objective Response Rate at Week 24 (ORR24W) — 32.1; 34.8 percentage of participants — p=0.2676
Early Phase 1 N=15 Topical Bimatoprost for Chemical Blepharoplasty
Dermatochalasis
Primary: Graded Change in Dermatochalasis — .2679 units on a scale
Phase 2 N=215 Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)
Atopic Dermatitis
Primary: Positive Anti-tetanus Response at Week 16 — 80; 73 Participants